News for ADiTx Therapeutics, Inc. (ADTX)

ADTX stock plunges to 52-week low, touches $0.18

Aditx Therapeutics stock hits 52-week low at $1.58

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.09%

These are the upcoming stock splits for the week of September 30 to October 4, based on TipRanks’ Stock Splits Calendar. A stock split is a corporate action in which the company issues additional common shares to increase the number of outstanding shares. Accordingly, the stock price of the company’s shares decreases, which maintains the market capitalization before and after the split. In contrast, there are also reverse stock splits that reduce the number of outstanding shares (consolidate). I

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.04%

Aditx Therapeutics (ADTX) said on Friday that it intends to execute a 1-for-40 reverse stock split to regain compliance with the Nasdaq’s minimum bid price requirement. The company’s common

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.15%

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.48%

U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.33%

Aditxt (ADTX) stock price dipped 48% on the purchase and sale of an aggregate of 1M shares at a purchase price of $10.00 per share in a private placement priced at the market under...

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their...

/PRNewswire/ -- The "COVID-19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Medical Devices Pipeline Assessment, 2020" report has been...

Today's Daily Dose brings you news about encouraging data related to AC Immune's vaccine candidate ACI-35.030 for the treatment of Alzheimer's disease; ESSA Pharma's prostate cancer trial results; GenMark's near-term catalyst; Infinity's urothelial cancer trial data; and Monopar's imaging agent to Improve surgical outcomes in bladder cancer.

Today's Daily Dose brings you news about FDA approval of Adamas' GOCOVRI for an expanded indication, positive results from Arcutis' plaque psoriasis trial, Concert Pharma's disappointing data from schizophrenia trial, and the progress in Clover's phase I adjuvanted trial of COVID-19 S-Trimer vaccine candidates, to name a few.

What's moving these stocks in pre-market hours today?.

Toward the end of trading Thursday, the Dow traded up 0.16% to 31,238.60 while the NASDAQ rose 0.63% to 13,541.78. The S&P also rose, gaining 0.20% to ...